Grant ID | RP100773 |
Awarded On | January 20, 2010 |
Title | Discovery and Validation of Novel Cancer Drug Targets through Synthetic Lethal Screening |
Program | Academic Research |
Award Mechanism | Individual Investigator |
Institution/Organization | The University of Texas M.D. Anderson Cancer Center |
Principal Investigator/Program Director | Gordon B Mills |
Cancer Sites | Basic Science, Multiple Sites |
Contracted Amount | $963,854 |
Lay Summary |
The goal of this project is to discover novel strategies to attack cancer cells. Unfortunately, many of the cancer drugs used today have strong toxic side effects because they do not target cancer cells specifically. Ideally, cancer drugs would target molecules whose disruption specifically kills cancer cells but does not harm normal cells. In the proposed research project, we aim to discover such ‘ideal’ drug targets. To do this, we performed a series of genome wide, high-throughput RNAi screens in human and Drosophila cultured cells to discover such drug targets referred to as “synthetic lethals.” We screened for genes whose knock-down specifically kills cells with hyperactivation of the A... |